专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US06492407B2 Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones 有权
标题翻译：含有三唑酮的药物组合物和使用三唑酮治疗神经变性疾病的方法
公开(公告)号：US06492407B2
公开(公告)日：2002-12-10
申请号：US09840281
申请日：2001-04-23
申请人： Michael Brenner , Wolf-Dietrich Bechtel , Rainer Palluk , Marion Wienrich , Thomas Weiser
发明人： Michael Brenner , Wolf-Dietrich Bechtel , Rainer Palluk , Marion Wienrich , Thomas Weiser
IPC分类号： A61K3141
CPC分类号： C07D401/04 , C07D249/12
摘要： A method for treating a neurodegenerative disease or cerebral ischemia arising from conditions selected from the group consisting of Status epilepticus, hypoglycaemia, hypoxia, anoxia, brain trauma, brain oedema, amyotropic lateral sclerosis, Huntington's disease, Alzheimer's disease, hypotonia, cardiac infarction, brain pressure (elevated intracranial pressure), ischaemic and haemorrhagic stroke, global cerebral ischaemia with heart stoppage, diabetic polyneuropathy, tinnitus, perinatal asphyxia, psychosis, schizophrenia, depression, and Parkinson's disease, the method of treatment comprising administering to a host in need of such treatment a therapeutic amount of a compound of formula (I) wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions containing a compound of formula (I).
摘要翻译：一种用于治疗由选自癫痫持续状态，低血糖，缺氧，缺氧，脑外伤，脑水肿，肌萎缩性侧索硬化，亨廷顿舞蹈病，阿尔茨海默氏病，低张力，心肌梗死，脑中的病症引起的神经变性疾病或脑缺血的方法压力（颅内压升高），缺血性和出血性中风，心脏停止的全球性脑缺血，糖尿病性多发性神经病，耳鸣，围产期窒息，精神病，精神分裂症，抑郁症和帕金森病，治疗方法包括向需要这种治疗治疗量的式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7如本文所定义，或其药学上可接受的盐，以及含有式（I）化合物的药物组合物，。

32. 发明授权

US06479523B1 Pharmacologic drug combination in vagal-induced asystole 有权
标题翻译：迷走神经诱发的心律失常药物组合
公开(公告)号：US06479523B1
公开(公告)日：2002-11-12
申请号：US09139442
申请日：1998-08-25
申请人： John D. Puskas
发明人： John D. Puskas
IPC分类号： A61K3141
CPC分类号： A61K31/452 , A61K31/138 , A61K31/275 , A61K31/277 , A61K31/44 , A61K31/445 , A61K2300/00
摘要： Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.
摘要翻译：冠状动脉旁路手术期间控制停止心跳，以及其他心脏手术在搏动心脏改善手术技术，通常通过电刺激迷走神经和施用药物组合来实现。

33. 发明授权

US06433019B1 Neurotrophic factor secretion promoters 失效
标题翻译：神经营养因子分泌促进剂
公开(公告)号：US06433019B1
公开(公告)日：2002-08-13
申请号：US09601186
申请日：2000-07-28
申请人： Hiroyuki Nawa
发明人： Hiroyuki Nawa
IPC分类号： A61K3141
CPC分类号： A61K31/5377 , A61K31/00 , A61K31/15 , A61K31/16 , A61K31/198 , A61K31/21 , A61K31/34
摘要： The present invention relates to a neurotrophic factor secretagogue, in particular, to a BDNF (brain-derived neurotrophic factor) secretagogue, which comprises as an active ingredient an NO donor. The medicament of the present invention promotes the secretion of neurotrophic factors from mammalian central neural cells. Thus, the medicament of the present invention, i.e., NO donor, is possibly applicable to the treatment of diseases caused by neutrotrophic factors, for example, neurodegenerative diseases, and is expected to exhibit the efficacious effects thereon. Also, the present invention provides a novel medication for neurodegenerative diseases.
摘要翻译：本发明涉及神经营养因子促分泌素，特别涉及BDNF（脑源性神经营养因子）促分泌素，其包含作为活性成分的NO供体。本发明的药物促进哺乳动物中枢神经细胞分泌神经营养因子。因此，本发明的药物即NO供体可能适用于治疗由中性营养因子引起的疾病，例如神经变性疾病，并且预期其对其有显着的效果。另外，本发明提供了用于神经变性疾病的新型药物。

34. 发明授权

US06414006B1 Methods for inhibiting bone resorption 失效
标题翻译：抑制骨吸收的方法
公开(公告)号：US06414006B1
公开(公告)日：2002-07-02
申请号：US09416733
申请日：1999-10-13
申请人： Shun-ichi Harada , Gideon A. Rodan , Mohamed Machwate , Marc LaBelle , Kathleen Metters , Robert N. Young
发明人： Shun-ichi Harada , Gideon A. Rodan , Mohamed Machwate , Marc LaBelle , Kathleen Metters , Robert N. Young
IPC分类号： A61K3141
CPC分类号： G01N33/88 , A61K31/00 , A61K31/4196 , A61K31/66 , A61K31/663 , A61K45/06 , G01N2500/04 , G01N2500/10 , A61K2300/00
摘要： The present invention relates to methods for inhibiting bone resorption in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of an EP4 receptor subtype antagonist.
摘要翻译：本发明涉及用于抑制哺乳动物骨吸收的方法，包括向有需要的哺乳动物施用治疗有效量的EP4受体亚型拮抗剂。

35. 发明授权

US06410582B1 Thienylazolylalcoxyethanamines, their preparation and their application as medicaments 失效
标题翻译：噻吩并噻唑基羟乙胺，它们的制备及其作为药物的应用
公开(公告)号：US06410582B1
公开(公告)日：2002-06-25
申请号：US09673186
申请日：2000-10-12
申请人： Ramon Merce-Vidal , Blas Andaluz-Mataro , Jordi Frigola-Constansa
发明人： Ramon Merce-Vidal , Blas Andaluz-Mataro , Jordi Frigola-Constansa
IPC分类号： A61K3141
CPC分类号： A61K31/4155 , C07D409/04 , C07D409/06
摘要： The thienylazolylalkoxyethanamines (I) where R1 is a hydrogen atom, a halogen atom or a lower alkyl radical; R2, R3 and R4 represent, independently, a hydrogen atom or a lower alkyl radical; and Az represents a five-member nitrogenated hetercyclic aromatic group, N-methyl-substituted, that contains from one to three nitrogen atoms. They have analgesic activity in mammals, including humans. The compounds (I) can be obtained, for example, by reaction of a derivative of hydroxy-thienylazol (IV) with a derivative of a suitable N-(ethyl)amine. The compounds (IV) are useful intermediates in the synthesis of the compounds (I). The compounds (I) have an application in human and/or veterinary medicine.
摘要翻译：其中R 1是氢原子，卤素原子或低级烷基的噻吩基唑烷基乙胺（I） R2，R3和R4独立地表示氢原子或低级烷基; 并且Az表示含有一至三个氮原子的五元氮杂环芳族基团N-甲基取代基。它们在哺乳动物，包括人类中具有止痛活性。化合物（I）可以通过例如羟基噻吩唑（IV）的衍生物与合适的N-（乙基）胺衍生物的反应来获得。化合物（IV）是化合物（I）的合成中的有用的中间体。化合物（I）在人和/或兽医学中有应用。

36. 发明授权

US06410542B1 Aminotetrazole derivatives useful as nitric oxide synthase inhibitors 失效
标题翻译：氨基四唑衍生物可用作一氧化氮合酶抑制剂
公开(公告)号：US06410542B1
公开(公告)日：2002-06-25
申请号：US09687350
申请日：2000-10-13
申请人： E. Ann Hallinan , Donald W. Hansen, Jr. , Sofya Tsymbalov
发明人： E. Ann Hallinan , Donald W. Hansen, Jr. , Sofya Tsymbalov
IPC分类号： A61K3141
CPC分类号： C07D239/42 , C07D231/40 , C07D233/88 , C07D249/14 , C07D257/06 , C07D277/18 , C07D277/46
摘要： The current invention discloses aminotetrazole derivatives useful as nitric oxide synthase inhibitors.
摘要翻译：本发明公开了用作一氧化氮合酶抑制剂的氨基四唑衍生物。

37. 发明授权

US06399641B1 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists 失效
标题翻译：具有治疗活性的2H-四唑酰胺化合物作为代谢型谷氨酸受体激动剂
公开(公告)号：US06399641B1
公开(公告)日：2002-06-04
申请号：US09892994
申请日：2001-06-27
申请人： Synese Jolidon , Vincent Mutel , Eric Vieira , Juergen Wichmann
发明人： Synese Jolidon , Vincent Mutel , Eric Vieira , Juergen Wichmann
IPC分类号： A61K3141
CPC分类号： C07D405/12 , C07D257/06 , C07D409/12
摘要： The present invention is a series of 2H-tetrazole-5-yl-amide derivatives showing activity as ligands of metabotropic glutamate receptors.
摘要翻译：本发明是一系列显示作为代谢型谷氨酸受体的配体活性的2H-四唑-5-基 - 酰胺衍生物。

38. 发明授权

US06369054B1 Aqueous agents for combating parasitic insects and acarina in human beings 有权
标题翻译：用于防治人类寄生昆虫和螨虫的水剂
公开(公告)号：US06369054B1
公开(公告)日：2002-04-09
申请号：US09601572
申请日：2000-08-03
申请人： Kirkor Sirinyan , Karin Horn , Ronald Helmut Stöcker , Rainer Sonneck
发明人： Kirkor Sirinyan , Karin Horn , Ronald Helmut Stöcker , Rainer Sonneck
IPC分类号： A61K3141
CPC分类号： A01N51/00 , A01N61/00 , A01N43/08 , A01N31/02 , A01N25/02 , A01N2300/00
摘要： The present invention relates to water-containing formulations for the dermal control of parasitic insects and mites on humans, said formulations having the following composition: a—agonists or antagonists of the nicotinic acetylcholine receptors of insects in a concentration of from 0.0001 to 7.5% by weight, based on the overall weight of the formulation; b—water in a concentration of from 20 to 50% by weight, based on the overall weight of the formulation; c—acyclic alcohols in a concentration of from 20 to 50% by weight, based on the overall weight of the formulation; d—solvents from the group consisting of cyclic carbonates and lactones in a concentration of from 2.5 up to 20.0% by weight, based on the overall weight of the formulation; e—optionally further auxiliaries from the group consisting of thickeners, spreading agents, colorants, antioxidants, propellants, preservatives, tackifiers, emulsifiers, in a concentration of from 0 up to 30% by weight, based on the overall weight of the formulation.
摘要翻译：本发明涉及用于真皮控制人类寄生昆虫和螨虫的含水制剂，所述制剂具有以下组成：昆虫的烟碱乙酰胆碱受体的α-激动剂或拮抗剂，其浓度为0.0001至7.5％，浓度为重量，基于制剂的总重量;基于制剂的总重量，浓度为20至50重量％的b-水;浓度为20至50重量％的c-无环醇，基于制剂的总重量;基于制剂总重量的2.5重量％至20.0重量％的来自环状碳酸酯和内酯的d-溶剂; e-任选的另外的辅助剂基于总重量的浓度为0至30重量％的增稠剂，铺展剂，着色剂，抗氧化剂，推进剂，防腐剂，增粘剂，乳化剂组成的组公式。

39. 发明授权

US06232331B1 Benzofuroxan derivatives, their therapeutic uses and pharmaceutical compositions 失效
标题翻译：苯并呋喃衍生物，其治疗用途和药物组合物
公开(公告)号：US06232331B1
公开(公告)日：2001-05-15
申请号：US09690805
申请日：2000-10-18
申请人： Alangudi Sankaranarayanan
发明人： Alangudi Sankaranarayanan
IPC分类号： A61K3141
CPC分类号： A61K31/4245 , C07D271/12
摘要： The invention discloses use of a compound of the benzofuroxan series for treatment of cardiovascular disorders represented by the general formula (I) and pharmaceutically acceptable salts thereof wherein: R is halogen, acetoxy, —X—R′, —C(O)NR″R′″, or —C(O)Cl; X is oxygen, sulfur, —C(O)—, or —C(O)O—; R′ is hydrogen, straight chain or branched lower alkyl (C1-C8); R″ and R′″ are independently hydrogen, straight chain or branched lower alkyl (C1-C8) or R″ and R′″ are linked together with or without a heteroatom selected from the group consisting of oxygen and nitrogen wherein substitution on nitrogen is with hydrogen or lower alkyl. The invention further discloses pharmaceutical compositions containing compounds of general formula I as active ingredients. The invention also discloses a method of treatment of mammal, including man, of coronary heart disease by administration of an effective amount of a compound of formula I as defined above.
摘要翻译：本发明公开了苯并呋喃酮系列化合物用于治疗由通式（I）表示的心血管疾病及其药学上可接受的盐的用途，其中：R为卤素，乙酰氧基，-X-R'，-C（O）NR' R'是-C（O）Cl; X是氧，硫，-C（O） - 或-C（O）O-; R'是氢，直链或支链的低级烷基（C1- C8）; R“和R”'独立地是氢，直链或支链的低级烷基（C1-C8）或R“和R”'与或不具有选自氧的杂原子连接在一起和氮，其中在氮上取代为氢或低级烷基。本发明还公开了含有通式I化合物作为活性成分的药物组合物。本发明还公开了一种通过给药治疗冠状动脉心脏病的哺乳动物（包括人）的方法有效量的如上定义的式I化合物。

40. 发明授权

US06211209B1 Method of inhibiting connective tissue degradation 失效
标题翻译：抑制结缔组织降解的方法
公开(公告)号：US06211209B1
公开(公告)日：2001-04-03
申请号：US09130215
申请日：1998-08-06
申请人： Vijaykumar Baragi , Diane Harris Boschelli , David Thomas Connor , Richard Raymond Renkiewicz , Howard Glenn Welgus
发明人： Vijaykumar Baragi , Diane Harris Boschelli , David Thomas Connor , Richard Raymond Renkiewicz , Howard Glenn Welgus
IPC分类号： A61K3141
CPC分类号： A61K31/433 , A61K31/341 , A61K31/4196 , A61K31/4245 , A61K31/426
摘要： The present invention provides a method of inhibiting connective tissue degradation that comprises administering to a patient having a condition in which connective tissue is degraded a therapeutically effective amount of a compound having the formula where R1, R2, R3, and R4 are independently hydrogen, hydroxy, halo, amino, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, CF3, CN, S(O)n—, R6 and R7 are independently hydrogen, C1-C6 alkyl, or acyl; n is 0 to 2; R8 is hydrogen or C1-C6 alkyl; W is S or O; Z is C1-C6 alkyl, C1-C6 alkoxy, or NR9R10; R9 and R10 are independently hydrogen or C1-C6 alkyl; and R5 is where Y is hydroxy, thiol, amino, or NHCN; X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof. Also provided is a method of inhibiting the production of matrix metalloproteinases comprising administering to a patient having a condition associated with matrix metalloproteinase-mediated tissue degradation a therapeutically effective amount of a compound having the formula where R1, R2, R3, and R4 are independently hydrogen, hydroxy, halo, amino, nitro, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkoxy, CF3, CN, S(O)n—, R6 and R7 are independently hydrogen, C1-C6 alkyl or acyl; n is 0 to 2; R8 is hydrogen or C1-C6 alkyl; W is S or O; Z is C1-C6 alkyl, C1-C6 alkoxy, or NR9R10; R9 and R10 are independently hydrogen or C1-C6 alkyl; and R5 is where Y is hydroxy, thiol, amino, or NHCN; X is sulfur or oxygen; and Q is sulfur, oxygen, NH, or NCN, and the pharmaceutically acceptable salts and prodrugs thereof.
摘要翻译：本发明提供了一种抑制结缔组织降解的方法，其包括对患有结缔组织降解的病症的患者施用治疗有效量的具有下式的化合物：R 1，R 2，R 3和R 4独立地为氢，羟基，卤素，氨基，硝基，C 1 -C 6烷基，C 3 -C 6环烷基，C 1 -C 6烷氧基，CF 3，CN，S（O）n - ，R 6和R 7独立地是氢，C 1 -C 6烷基或酰基; n是0 R 2是氢或C 1 -C 6烷基; W是S或O; Z是C 1 -C 6烷基，C 1 -C 6烷氧基或NR 9 R 10; R 9和R 10独立地是氢或C 1 -C 6烷基; 和R 5是其中Y是羟基，硫醇，氨基或NHCN; X是硫或氧; 和Q是硫，氧，NH或NCN，及其药学上可接受的盐和前药。还提供了抑制基质金属蛋白酶产生的方法，包括对具有与基质金属蛋白酶介导的组织降解有关的病症的患者施用治疗有效量的具有下式的化合物：R1，R2，R3和R4独立地是氢，羟基，卤素，氨基，硝基，C1-C6烷基，C3-C6环烷基，C1-C6烷氧基，CF3，CN，S（O）n，R6和R7独立地是氢，C1-C6烷基或酰基; n是 0至2; R 8是氢或C 1 -C 6烷基; W是S或O; Z是C 1 -C 6烷基，C 1 -C 6烷氧基或NR 9 R 10; R 9和R 10独立地是氢或C 1 -C 6烷基; 和R 5是其中Y是羟基，硫醇，氨基或NHCN; X是硫或氧; 和Q是硫，氧，NH或NCN，及其药学上可接受的盐和前药。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式